Safety and efficacy of supported, at-home, sublingual ketamine telehealth for depression: New findings from a large, open-label effectiveness trial.

Summarise with VIRAT
Authors: David S. Mathai, Leonardo Vando, Thomas D. Hull, Matteo Malgaroli
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Our aim for the present study is to replicate previous analysis of supported, at-home, sublingual ketamine telehealth for depression in a substantially larger patient sample (n ~ 10,000) obtained through ongoing data collection with the same telemedicine platform and to further clarify the safety and efficacy of this therapeutic modality. Building on the previous findings, we will investigate new data including the average ketamine dose prescribed to patients, the qualifications of ketamine prescribers (e.g., degree types), and characteristics/outcomes for patients who opted for a second round of ketamine treatment. We will also utilize longitudinal trajectory and network analyses to further describe the overall study population and to explore predictors of treatment outcome, which could inform personalized clinical decision-making with ketamine.

Fields of Study & Subjects

Treatment of Major Depression Electroconvulsive Therapy Studies Telemedicine and Telehealth Implementation

Publication details

Journal / source
OSF Preprints (OSF Preprints)
Publication date
24 March 2026
Language
EN
Document type
Preprint